1. Home
  2. INTS vs VTGN Comparison

INTS vs VTGN Comparison

Compare INTS & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$5.81

Market Cap

19.2M

Sector

Health Care

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.59

Market Cap

21.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTS
VTGN
Founded
2012
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.2M
21.8M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
INTS
VTGN
Price
$5.81
$0.59
Analyst Decision
Strong Buy
Hold
Analyst Count
2
3
Target Price
$56.25
$0.90
AVG Volume (30 Days)
19.4K
417.5K
Earning Date
05-12-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.43
52 Week High
$8.06
$5.14

Technical Indicators

Market Signals
Indicator
INTS
VTGN
Relative Strength Index (RSI) 48.61 45.48
Support Level $0.29 $0.57
Resistance Level $8.06 $0.60
Average True Range (ATR) 0.39 0.04
MACD -0.28 0.00
Stochastic Oscillator 12.90 35.85

Price Performance

Historical Comparison
INTS
VTGN

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Share on Social Networks: